196170 — Alteogen Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapMomentum Trap

Market Cap
KR₩20tn
Enterprise Value
KR₩20tn
Revenue
KR₩103bn

Annual income statement for Alteogen, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	42,426	38,746	28,806	96,523	102,855
Cost of Revenue
Gross Profit	18,756	5,789	4,531	31,199	64,069
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	42,290	52,033	47,065	104,868	79,971
Operating Profit	136	-13,287	-18,259	-8,345	22,884
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-2,839	-10,694	-9,970	-3,564	36,612
Provision for Income Taxes
Net Income After Taxes	-3,422	-11,588	-10,078	-3,582	60,690
Minority Interest
Net Income Before Extraordinary Items
Net Income	-970	-6,275	-8,146	-3,372	62,252
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-970	-6,275	-8,146	-3,372	62,737
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-18	-124	-301	-57	1,203
Dividends per Share